Inside Celsense

Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.

Celsense is a privately held biotechnology company offering novel MRI agents that allow scientists and clinicians to monitor the location and quantity of transplanted cells. The company’s products have application in the fields of regenerative medicine, immunotherapy, and the study of inflammation and immune system response. Celsense is currently collaborating with leading pharmaceutical and biotechnology organizations and is developing products suitable for human use.

Celsense was founded in 2005 to commercialize imaging platforms developed at Carnegie Mellon University.

Charlie O'Hanlon

President and CEO [LinkedIn]

Charles F. O’Hanlon serves as the company’s President and CEO. Mr. O’Hanlon was previously a Managing Director of Cornerstone Capital Advisors, of Pittsburgh, PA, where he provided financial and operating advice, interim management, and corporate finance services to privately held businesses. While at Cornerstone, he was involved in the founding of numerous new ventures, spin-offs, and re-starts of distressed companies. Prior to joining Cornerstone in 2001, he held a number of executive management positions with National City and Mellon Bank. Mr. O’Hanlon serves on the boards of several private companies. He previously served on the boards of the Pittsburgh Technology Council, the CEO Venture Fund, and the Pittsburgh Regional Healthcare Initiative. He received a B.S. in industrial management from Georgia Institute of Technology and an MBA from Robert Morris College in 1980.

Lourdes Castellanos

Controller and Secretary [LinkedIn]

Lourdes M. Castellanos, MBA serves as Controller and Secretary for the company. Ms. Castellanos was previously a community volunteer. Her volunteer activities centered on K-12 public education, non-partisan voter education, and other community centered activities. Ms. Castellanos began her career as a Federal and international tax analyst for Consol Energy. She received her B.S. in Industrial Management from Georgia Tech and an MBA from the University of North Carolina Chapel Hill.

Brooke Helfer, Ph.D.

Director of Research and Development [LinkedIn]

Brooke M. Helfer, Ph.D., serves as the company’s Director of Research and Development. Dr. Helfer’s primary research interests relate to translational cancer immunotherapy, promoting the development of cellular therapeutics, and the advancement of future scientists. Dr. Helfer completed her Ph.D. in Cancer Cell Biology in the Mary Babb Randolph Cancer Center at the West Virginia University Health Science Center, and her B.A. in Biology and German from Washington and Jefferson College in Washington, PA.

Celsense Leadership

BOARD OF DIRECTORS

  • Paul Kornblith, M.D., Chairman
  • Jeffrey S. Friedman, M.D., Ph.D.
  • Gregory T. Hebrank, M.D.
  • Charles F. O’Hanlon, President and CEO
  • Thomas Petzinger, Jr.
  • L. Gerald Tarantino, J.D.

SCIENTIFIC ADVISORY BOARD

  • D. Lansing Taylor, Ph.D.
  • Eric T. Ahrens, Ph.D

Latest News

 

Continue Exploring

Products

Click here

Papers

Click here

Real-Time Results,<br />Faster and More Accurate

Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.

GET IN TOUCH

Send Us A Message

© 2018 Celsense, Inc. All rights reserved.